On 29 May, the Mixed Chamber of the Cour de cassation (France’s Supreme Court, pictured) ruled that préjudice d’anxiété – anxiety suffered by individuals exposed to a hazardous substance who fear developing a serious illness in the future – is a bodily injury and is therefore subject to the 10-year limitation period applicable to personal injury claims.
At first sight, the ruling appears to concern a technical statute of limitation issue. In reality, it represents a further step in the steady expansion of French toxic tort litigation and may have important consequences for businesses, insurers and multinational defendants operating across Europe.
Indeed, the decision illustrates a growing judicial willingness to recognise legal consequences arising from exposure to a risk, even where no disease has yet materialised or will ever materialise.
Anxiety damage first emerged from asbestos litigation. French courts accepted that workers exposed to asbestos could suffer compensable harm through the psychological burden associated with the risk of developing a potentially fatal disease. What was initially conceived as a specific remedy for asbestos exposure progressively evolved into a much broader cause of action. In 2019, the Mixed Chamber significantly widened its scope by allowing claims from workers exposed to any harmful substance capable of creating a high risk of serious illness. Since then, anxiety claims have increasingly appeared in litigation involving environmental contamination, pharmaceutical products, pesticides, industrial emissions and other alleged toxic exposures.
Yet an important legal uncertainty remained. Was anxiety damage an autonomous moral injury, or was it a bodily injury itself?
The answer mattered because French law applies different limitation periods depending on the nature of the harm (five-year or even two-year limitation periods), while bodily injury claims benefit from a 10-year period.
The issue eventually reached the Mixed Chamber in litigation involving prenatal exposure to diethylstilbestrol (DES), a synthetic hormone prescribed to pregnant women for decades before serious health concerns emerged. The court adopted a broad conception of bodily injury. It held that bodily injury encompasses both physical and psychological impairments affecting personal integrity. As a result, anxiety claims linked to toxic exposure in France are now subject to a 10-year limitation period.
For claimants, this decision strengthens an already powerful cause of action. For businesses and insurers, however, the implications are potentially far more significant than the limitation issue itself.
The most obvious consequence is the expansion of litigation exposure. Claims that might previously have been vulnerable to limitation defences may now proceed. This is particularly relevant in sectors involving long-latency risks, including pharmaceuticals, chemicals, pesticides, industrial manufacturing and environmental activities.
The broader concern lies elsewhere. Unlike traditional personal injury litigation, anxiety claims do not require proof of a diagnosed disease. The alleged injury consists of the psychological burden associated with the possibility of future illness.
From a defence perspective, this development raises difficult questions concerning the boundaries of civil liability, as traditionally tort law has focused on compensating harm that has already materialised. Anxiety damage, therefore, shifts the focus towards the consequences of a future risk that may never ultimately result in disease.
This ruling is particularly significant because many exposure claims concern products or substances that were lawfully manufactured, marketed or used at the relevant time. Businesses may therefore face increasing liability exposure despite having complied with the scientific and regulatory framework then in force. As scientific knowledge evolves and perceptions of risk change, historical conduct that was considered lawful may become the subject of substantial litigation many years later.
The decision also has implications for insurers and reinsurers. Exposure-based liabilities have always presented particular challenges because claims often emerge decades after the underlying conduct occurred. However, by extending the applicable limitation period and reinforcing a cause of action that does not depend on the manifestation of disease, the French Supreme Court has increased uncertainty regarding both the duration and potential scale of future liabilities.
For practitioners in England and Wales, the immediate legal impact could be perceived as limited, particularly as English law has traditionally been more cautious than French law in recognising claims based solely on fear of future illness. While damages may be recoverable for recognised psychiatric injury in certain circumstances, English courts have generally resisted attempts to compensate anxiety arising from exposure to a potentially harmful substance in the absence of an established injury.
Nevertheless, the French decision arrives at an interesting moment for the UK legal market. The High Court is currently facing large-scale talc litigation, with thousands of claimants alleging that talc-based products caused ovarian cancer, mesothelioma and other diseases. The recent grant of a Group Litigation Order reflects the growing importance of mass tort litigation in England and Wales.
The French judgment could give rise to the idea of adding claimants to the talc claim who have not materialised a diagnosed disease, or for those who have, to add a head of loss to their existing claim.
Claimant firms involved in environmental, product liability and group litigation are increasingly exploring novel theories of loss. The anxiety damage argument will be attractive because the number of individuals exposed to a substance generally exceeds the number who have developed an illness. Similar debates are emerging internationally about PFAS (perfluoroalkyl and polyfluoroalkyl substances), pesticides, industrial emissions and pharmaceutical products.
The French approach offers claimants a mechanism to bridge that gap by transforming exposure-related anxiety into a compensable head of damage. It extends a limitation period, but it further blurs the distinction between proven injury and perceived risk. If similar arguments were ever to gain traction in England and Wales, the consequences for businesses and insurers would be considerable, particularly in the context of group actions.
At a time when litigation involving talc, PFAS, pesticides and other allegedly harmful substances is gaining momentum across multiple jurisdictions, the judgment signals a continuing expansion of exposure-based liability.
Sylvie Gallage-Alwis is a partner at Signature Litigation, Paris
No comments yet